This Project Grant award of $429,000 from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) supports research to understand the cellular and synaptic mechanisms underlying cognitive disabilities in Down syndrome. The award to the University of Colorado-Denver will utilize a novel combination of two-photon microscopy, electrophysiology, chemogenetics, and pharmacological...
The federal Cooperative Agreement award U01HD116463, titled "The Infant Down Syndrome Brain and Behavior Study", is funded by the National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310). The $2,927,457 award will support a longitudinal study to collect multimodal neuroimaging, cognitive/behavioral data, and social communication measures in a cohort of 100 infants with Down syndrome and 50 typically developing controls. The study aims to...
This Project Grant award of $3,317,325.00 from the National Institutes of Health's Trans-NIH Research Support program (CFDA 93.310) will support research to investigate the role of immune dysregulation and nerve growth factor (NGF) dysfunction in the development of Alzheimer's disease (AD) in individuals with Down syndrome (DS). The key objectives are to: 1) elucidate the relationships between immune deregulation, NGF dysmetabolism, and AD hallmarks in DS brain tissue and cell cultures; 2)...
This federal Project Grant award from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310) provides $2,357,335 to study neuronal dysfunction in Down syndrome (DS) and its link to Alzheimer's disease (AD). The key products and services delivered under this award include: Utilizing induced pluripotent stem cell (iPSC)-derived cortical organoids and assembloids to examine the cellular, transcriptomic, and motility-related...
This Project Grant award from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), under the Child Health and Human Development Extramural Research program (CFDA 93.865), provides $661,575 to Children's Hospital LOS Angeles to conduct a 5-year study on Down Syndrome Regression Disorder (DSRD). The research aims to utilize neurodiagnostic studies, proteomic, and metabolomic analyses to compare individuals with DSRD to those with Down Syndrome who do not...
This $2,598,199 Cooperative Agreement, awarded by the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310), will support a multi-center, multi-disciplinary research project titled "Advancing the Lives & Health of Youth and Young Adults with Down Syndrome (ALLY-DS)." The project aims to establish a diverse cohort of individuals with Down syndrome for comprehensive longitudinal phenotyping, including multi-omics data...
This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) in the amount of $195,041 supports research to elucidate the role of cardiovascular disease in the development of Alzheimer's disease in individuals with Down syndrome. The 2-year project will leverage data from the Alzheimer's Biomarker Consortium for Down Syndrome to develop innovative statistical models combining Bayesian inference and machine learning. These methods will explore...
The National Institutes of Health (NIH) awarded a $2,507,286 Project Grant under the Trans-NIH Research Support program (CFDA 93.310) to investigate therapies for Down Syndrome Regression Disorder (DSRD). The 3-year grant, which commenced on September 1, 2024, supports a comparative clinical trial evaluating the safety and efficacy of three potential DSRD treatments: the benzodiazepine lorazepam, intravenous immunoglobulin (IVIG), and the JAK inhibitor tofacitinib. The project aims to advance...
The National Institutes of Health (NIH) Office of the Director awarded a Project Grant of $1,896,457.00 under the Trans-NIH Research Support program (CFDA 93.310) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), for the project "BRAIN DEVELOPMENT IN DOWN SYNDROME DURING FETAL AND EARLY POSTNATAL AGES". The grant, awarded on Sep 18, 2024, aims to confirm earlier findings on brain abnormalities in Down syndrome (DS) using advanced...
The Department of Health and Human Services, through the Trans-NIH Research Support program (CFDA 93.310), has awarded a $1,999,508 Cooperative Agreement to RTI International and Emory University to establish the INCLUDE Down Syndrome Clinical Cohort Coordinating Center (DS-4C). The DS-4C will serve as the central hub to coordinate and integrate all components of the INCLUDE Down Syndrome Cohort Development Program, including overseeing protocol development, facilitating data collection and...